A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Phase 2
416
about 1.5 years
18+
37 sites in AL, CA, FL +16
What this study is about
This trial is testing whether a treatment combining vicadrostat and empagliflozin helps people with chronic kidney disease. This treatment will be compared to a placebo combined with empagliflozin for some participants. It lasts about 4.5 months, during which doctors monitor kidney function and check for any side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Empagliflozin
- 2.Take Placebo matching vicadrostat
- 3.Take Vicadrostat
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
oral (Oral Tablet)
Primary: Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 14 and week 16
Secondary: Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 12, Absolute change in systolic blood pressure (SBP) (mmHg) from baseline to Week 12, Relative change (ratio) in Urine Albumin Creatinine Ratio (UACR) from baseline to Week 6
Renal